FDA revises monitoring for SCLC therapy

• by Kathryn Wighton

• September 15, 2026

Predicting 5-Year Mortality in Non–Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study

• by Jong Hyuk Lee, Ho Cheol Kim, Kyu-Won Jung, Chang Min Choi

• June 8, 2026

Screening Eligibility and Survival Among Patients With Lung Cancer in Korea

• by Yeon Wook Kim, Tae Ho Yoon, Kyeong Im Kwak, Minji Han, Eung Joo Park, Choon-Taek Lee

• July 21, 2026

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

• June 9, 2026

• 5 min